Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Virpax Pharmaceuticals ( (VRPX) ) has provided an update.
On April 2, 2025, Virpax Pharmaceuticals received a delisting notice from the Nasdaq Hearings Panel due to non-compliance with the minimum stockholders’ equity requirement. The company’s stock trading will be suspended on April 4, 2025, with delisting finalized after the appeal period. Additionally, on the same day, several board members and the CFO resigned, with no disagreements cited as the cause.
More about Virpax Pharmaceuticals
YTD Price Performance: -87.16%
Average Trading Volume: 364,334
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.59M
Learn more about VRPX stock on TipRanks’ Stock Analysis page.